A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

NCT00002016 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Retinitis
HIV Infections

Interventions

DRUG: Sevirumab

Sponsor

Sandoz